Zenith Technologies sees 400% China growth in latest Asia success
Company plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.
Zenith Technologies, a world leader in delivering manufacturing software solutions to the life sciences industry, has reported 400% growth in its Chinese operations in the last 3 years.
The company now has a presence working on sites across five Chinese cities – Shanghai, Suzhou, Xi’an, Hangzhou & Guangzhou - and employs a growing team to work across its client base supporting pharma and biotech companies with the implementation of technologies to improve manufacturing efficiencies such as automation, IT, manufacturing execution systems (MES) and digital and data analysis.
With the Chinese life sciences market currently set as the world’s second largest national market, and with an expected value of $220 billion by 2022, Zenith plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.
Liang Zhou, General Manager of Greater China said: “The Chinese market has been leading the way in revolutionary cell therapy innovations, which are changing the face of medicine delivery. There is growing interest in the adoption of automating processes in this area as companies build a new generation of facilities in line with stringent international standards with a view to supplying across the world.
“We are well placed to support clients here who would like to adopt these solutions and have already played an integral role in the development of technologies to oversee these key cell therapy innovations.”
Zenith’s success in China represents the company’s latest endeavour in the Asian market having first set up a presence on the continent in 2002 with the opening of its regional headquarters in Singapore.
In 2008 the company set up an office in India, which now hosts more than 100 employees and serves as a global support hub to deliver software projects anywhere in the world, featuring a remote engineering centre and 24/7 IT support desk service.
Across the continent, Zenith now has a total workforce of more than 200 professionals and is actively looking to new Asian markets to expand its footprint to support the burgeoning number of life science hubs.
Bryan McSwiney, Asia Director said: “After more than 15 years in the Asian market, a quarter of our global operations are now based here and the latest growth figures from China demonstrate that we go from strength to strength.
“We now have an established presence in five Chinese cities – a significant footprint within a relatively short space of time – as well as a thriving support hub in India and a widely recognised HQ in Singapore.
“With a solid foundation now firmly established in the Asian market, we look forward to building on our successes and working closely with local and multinational companies on the continent who can benefit from the diverse range of technologies we can introduce into manufacturing facilities.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance